BC
GOSS icon

Bridgefront Capital’s Gossamer Bio GOSS Stock Holding History

Bridgefront Capital’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,750
Closed -$111K – 350
2022
Q1 		$111K Buy
+12,750
New +$123K 0.14% 230
2021
Q2 		– Sell
-13,672
Closed -$126K – 715
2021
Q1 		$126K Sell
13,672
-5,116
-27% -$51.6K 0.04% 610
2020
Q4 		$182K Buy
+18,788
New +$185K 0.06% 531

Other funds holding GOSS

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridgefront Capital's GOSS Position: Q2 2022 in Review

Bridgefront Capital sold out of Gossamer Bio (GOSS) in Q2 2022, closing a stake of 12,750 shares — an estimated $111K sold.

Bridgefront Capital first reported a position in GOSS in Q4 2020 and held it in 3 quarters. The position peaked at $182K in Q4 2020. 129 funds tracked by Wall St. Rank hold GOSS as of Q2 2022.

  • Bridgefront Capital reported no remaining Gossamer Bio position as of Q2 2022 after selling out during the quarter.
  • Bridgefront Capital sold 12,750 Gossamer Bio shares in Q2 2022, an estimated $111K.
  • Bridgefront Capital first reported a position in Gossamer Bio in Q4 2020 and held it in 3 quarters.
  • Bridgefront Capital's Gossamer Bio position peaked at $182K in Q4 2020.
  • 129 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2022.

Based on Bridgefront Capital's 13F filing for Q2 2022, filed 12 Aug 2022.